Status:
COMPLETED
Telemedicine on Metabolic Control in Type 1 Diabetes Mellitus Andalusian Patients (PLATEDIAN)
Lead Sponsor:
Sociedad Andaluza de Endocrinología, Diabetes y Nutrición
Conditions:
Telemedicine
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
To assess the effect of a 6-month telemedicine program (DiabeTIC) in patients with type 1 diabetes mellitus (DM1) and regular metabolic control (HbA1c \<8%) in multi-dose insulin treatment (MDI) measu...
Detailed Description
The substitution of face-to-face visits for telematics visits has a similar effect on glycemic control (measured by HbA1c) in patients with DM1 treated with multiple daily doses of insulin (MDI) and r...
Eligibility Criteria
Inclusion
- Patients with DM1 over 2 years of evolution.
- Age ≥18 and \<65 years.
- HbA1c prior to inclusion of the study \<8% (the measure being valid in the month prior to inclusion in the study)
- Intensive insulin therapy with basal-bolus MDI.
- Patients living in Andalusian
- Patients candidates for telemonitoring.
- Patients who have received written informed consent.
Exclusion
- Treatment with ISCI.
- Chronic kidney disease, liver disease, thyroid dysfunction (except hypothyroidism correctly treated and controlled).
- Pregnancy or pregnancy planning.
- Diabetes mellitus type 2.
- Severe psychological disturbances.
- Absence of collaboration (informed consent).
- Patients who are participating in other clinical studies.
Key Trial Info
Start Date :
December 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2016
Estimated Enrollment :
334 Patients enrolled
Trial Details
Trial ID
NCT03332472
Start Date
December 1 2013
End Date
December 1 2016
Last Update
November 6 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Regional Universitario de Málaga. Unidad de Diabetes
Málaga, Spain, 29010